Search Result

Pathways Recommended:	Antibody-drug Conjugate/ADC Related

Results for "

antibody+conjugate

" in MedChemExpress (MCE) Product Catalog:

By Targets:	ADC Antibody (2) ADC Linker (10) ADC Payload (6) Antibody-Drug Conjugates (ADCs) (7) Biochemical Assay Reagents (1) CD22 (1) CD74 (1) Drug Intermediate (2) Drug-Linker Conjugates for ADC (12) E3 Ligase Ligand-Linker Conjugates (1) Ephrin Receptor (1) Epigenetic Reader Domain (2) Fluorescent Dye (2) GLP Receptor (1) Insulin Receptor (1) Isotope-Labeled Compounds (2) Microtubule/Tubulin (7) Nectin-4 (2) NF-κB (1) PD-1/PD-L1 (1) PROTAC-Linker Conjugates for PAC (1) PROTACs (2) Radionuclide-Drug Conjugates (RDCs) (1) SARS-CoV (1) STING (3) Toll-like Receptor (TLR) (5) Topoisomerase (3) Transmembrane Glycoprotein (3)
By Research Areas:	Cancer (44) Infection (1) Inflammation/Immunology (5) Metabolic Disease (1)
Click Chemistry:	ADC Synthesis (2) DBCO (2)

Inhibitors & Agonists

Fluorescent Dyes

Biochemical Assay Reagents

Inhibitory Antibodies

Isotope-Labeled Compounds

Click Chemistry

GMP Molecules

Cat. No.	Product Name	Target	Research Areas	Chemical Structure

HY-19792

Mertansine Maximum Cited Publications 27 Publications Verification DM1; Maytansinoid DM1	Microtubule/Tubulin ADC Payload	Cancer
Mertansine (DM1) is a microtubulin inhibitor and is an antibody-conjugatable maytansinoid that is developed to overcome systemic toxicity associated with maytansine and to enhance tumor-specific delivery. Mertansine can be attached to a monoclonal antibody with a linker to create an antibody-drug conjugate (ADC) .

HY-P99016B

Enfortumab vedotin-ejfv (solution) 1 Publications Verification	Antibody-Drug Conjugates (ADCs) Nectin-4	Cancer
Enfortumab vedotin-ejfv (solution) is an anti-Nectin-4 antibody-drug conjugate (ADC). Enfortumab vedotin-ejfv (solution) is a fully humanized IgG1 antibody conjugated to the microtubule disrupting agent MMAE (HY-15162) via a protease-cleavable Val-Cit linker. The antibody portion is Enfortumab (HY-P99016), and the drug-linker conjugate for ADC is VcMMAE (HY-15575). Nectin-4 is an adhesion protein involved in cellular processes and tumorigenesis, and Enfortumab vedotin-ejfv (solution) is indicated for the inhibition of locally advanced or metastatic urothelial carcinoma .

HY-114233

MC-GGFG-Exatecan 5+ Cited Publications MC-GGFG-DX8951	Drug-Linker Conjugates for ADC Topoisomerase	Cancer
MC-GGFG-Exatecan (MC-GGFG-DX8951) is a agent-linker conjugate for ADC. MC-GGFG-Exatecan is a DX8951 (a DNA topoisomerase I inhibitor) derivative with protease cleavable MC-GGFG linker. MC-GGFG-Exatecan shows antitumor activity and can be used to prepare DX8951 antibody conjugate (ADC) .

HY-P99016A

Enfortumab vedotin-ejfv 1 Publications Verification	Antibody-Drug Conjugates (ADCs) Nectin-4	Cancer
Enfortumab vedotin-ejfv is an anti-Nectin-4 antibody-drug conjugate. Enfortumab vedotin-ejfv is a fully humanized IgG1 antibody conjugated to the microtubule disrupting agent MMAE (HY-15162) via a protease-cleavable Val-Cit linker. The antibody portion is Enfortumab (HY-P99016), and the drug-linker conjugate for ADC is VcMMAE (HY-15575). Nectin-4 is an adhesion protein involved in cellular processes and tumorigenesis, and Enfortumab vedotin-ejfv is indicated for the inhibition of locally advanced or metastatic urothelial carcinoma .

HY-19318

Fmoc-Val-Cit-PAB	ADC Linker	Cancer
Fmoc-Val-Cit-PAB is a cleavable antibody-conjugated active molecule (ADC) commonly used linker.

HY-164535

Maridebart cafraglutide AMG 133	Antibody-Drug Conjugates (ADCs) GLP Receptor Insulin Receptor	Metabolic Disease
Maridebart cafraglutide (AMG 133) is a long-acting peptide-antibody conjugate that combines GLP-1 receptor agonist with glucose-dependent insulinotropic polypeptide (GIP) receptor antagonism. Maridebart cafraglutide shows antagonist activity against human, cynomolgus monkey and rat GIPR with IC₅₀ values of 46.4 nM, 26.5 nM, 822.3 nM, respectively. Maridebart cafraglutide shows agonist activity against human, cynomolgus monkey, rat and mouse GLP-1R with EC₅₀ values of 24.4 pM, 5.7 pM, 2.4 pM and 123 pM, respectively. Maridebart cafraglutide can be used for the study of obesity and type 2 diabetes .

HY-150233

Cys-McMMAF	Microtubule/Tubulin	Cancer
Cys-McMMAF is the released payload of AlMcMMAF, an anti-5T4 humanized A1 antibody conjugated to the microtubule disrupting MMAF (HY-15579) via a maleimidocaproyl linker. Cys-McMMAF has antitumor efficacy in two tumor mouse models (H1975 and MDA-MB-361-DYT2 models) .

HY-128870

Mal-PEG2-VCP-Eribulin	Drug-Linker Conjugates for ADC	Cancer
Mal-PEG2-VCP-Eribulin consists the ADCs linker (Mal-PEG2-VCP) and Eribulin (HY-13442). Eribulin is a mechanistically unique microtubule inhibitor and Eribulin inhibits the proliferation of cancer cells by binding microtubule proteins and microtubules. Mal-PEG2-VCP-Eribulin is an Eribulin-based agent for antibody conjugates .

HY-153360

MC-GGFG-AM-(10Me-11F-Camptothecin)	Drug-Linker Conjugates for ADC Topoisomerase	Cancer
MC-GGFG-AM-(10Me-11F-Camptothecin) is a linker-payload conjugate used to synthesize ZW251. ZW251 an antibody-drug conjugate (ADC) targeting human GPC3. ZW251 consists of a humanized IgG1 antibody conjugated to a novel camptothecin-based topoisomerase 1 inhibitor, ZD06519, via a linker. The linker is the maleimide anchor and a glycyl glycyl phenylalanyl glycine (GGFG)-aminomethyl (AM) cleavable linker. ZW251 has high affinity with human and cynomolgus monkey GPC3. ZW251 displays rapid internalization in GPC3-expressing HCC cell lines, and bystander-mediated killing of GPC3 negative cancer cells .

HY-171821

PF-08046054 SGN-PDL1V	Antibody-Drug Conjugates (ADCs) PD-1/PD-L1	Cancer
PF-08046054 (SGN-PDL1V) is a PD-L1-directed Antibody-drug conjugate (ADC), which is comprised of an anti-PD-L1 antibody conjugated to VcMMAE (HY-15575). PF-08046054 is direct cytotoxicity to PD-L1-expressing tumor cells via the intracellular delivery of MMAE. PF-08046054 can be used for the study of solid tumors

HY-141606

Anetumab ravtansine BAY 94-9343	Microtubule/Tubulin Antibody-Drug Conjugates (ADCs)	Cancer
Anetumab ravtansine (BAY 94-9343) is a selective and highly potent **antibody-drug conjugate (ADC) to target maytansinoid tubulin*. Anetumab ravtansine consists of a human anti-mesothelin antibody conjugated* to the maytansinoid tubulin inhibitor DM4. Anetumab ravtansine shows antitumor efficacy correlated with the amount of mesothelin expressed in patient-derived xenograft tumor models .

HY-P9959

Inotuzumab ozogamicin CMC-544; PF-5208773; WAY-207294	Antibody-Drug Conjugates (ADCs) CD22	Cancer
Inotuzumab ozogamicin (CMC-544) is an antibody-targeted chemotherapy agent composed of a humanized anti-CD22 antibody conjugated to Calicheamicin (HY-19609). Inotuzumab ozogamicin and G544 bind human CD22 with similar affinities (K_d ≈ 150 pM). Inotuzumab ozogamicin has demonstrated efficacy against CD22 ⁺ B-cell non-Hodgkin’s lymphoma. Inotuzumab ozogamicin can be used in the research of acute lymphoblastic leukemia .

HY-171792

BMS-986497 ORM-6151	Transmembrane Glycoprotein	Cancer
BMS-986497 (ORM-6151) is a CD33-targeting antibody-conjugated GSPT1 degrader. BMS-986497 delivers the GSPT1 degrader SMol006 to CD33-expressing cells and induces GSPT1 protein degradation. BMS-986497 shows potential for research on acute myeloid leukemia (AML) .

HY-P991501

Meplazumab HcHAb18	ADC Antibody Transmembrane Glycoprotein SARS-CoV	Infection Cancer
Meplazumab (HcHAb18) is a humanized anti-CD147 IgG1 antibody a K_d of 0.47 nM. Meplazumab shows anti-SARS-CoV-2 and antitumor activity. Meplazumab conjugated with DM1 can form an antibody-conjugated drug ( HcHAb18-DM1), which induces G2/M phase cell cycle arrest and exerts antiproliferative activity in cancer cells. Meplazumab can be used for the researches of COVID-19 pneumonia and non-small cell lung cancer .

HY-P990627

Anti-EphA2 Antibody (1C1) MEDI-547 antibody	ADC Antibody Ephrin Receptor	Cancer
Anti-EphA2 Antibody (1C1) (MEDI-547 antibody) is an anti-EphA2 monoclonal antibody. Anti-EphA2 Antibody (1C1) can induce degradation of EphA2 protein. Anti-EphA2 Antibody (1C1) conjugated with McMMAF (HY-15578) can form an antibody-conjugated drugs, which has potent antitumor activity. Anti-EphA2 Antibody (1C1) can be used for the research of cancer, such as prostate cancer and glioma .

HY-13631F

Gly-Gly-Phe-Gly-NH-O-CO-Exatecan hydrochloride	Drug-Linker Conjugates for ADC Topoisomerase	Cancer
Gly-Gly-Phe-Gly-NH-O-CO-Exatecan, as a drug-linker conjugate composed of linker Gly-Gly-Phe-Gly-NH-O-CO and Exatecan, can be used to prepare antibody conjugate drugs. Exatecan is a DNA topoisomerase I inhibitor that can be used in cancer research .

HY-148127

TAM558	Drug-Linker Conjugates for ADC	Cancer
TAM558 is a payload molecule used for the synthesis of OMTX705. OMTX705 is a humanized anti-fibroblast-activating protein (FAP) antibody conjugated to the cytolysin TAM470 (HY-148128), with antitumor activity .

HY-161022A

FL118-C3-O-C-amide-C-NH2 formate	ADC Linker	Cancer
FL118-C3-O-C-amide-C-NH2 format is an ADC linker for the synthesis of synthetic antibody conjugate active molecules (ADCs)..

HY-136261

DM1-PEG4-DBCO	Drug-Linker Conjugates for ADC	Cancer
DM1-(PEG)4-DBCO is a agent-linker conjugate composed of a potent microtubulin inhibitor DM1 and a linker DBCO-PEG4-Ahx to make antibody agent conjugate (ADC). Mertansine (DM1) is a microtubulin inhibitor and is an antibody-conjugatable maytansinoid that is developed to overcome systemic toxicity associated with maytansine and to enhance tumor-specific delivery. DM1-PEG4-DBCO is a click chemistry reagent, it contains a DBCO group that can undergo strain-promoted alkyne-azide cycloaddition (SPAAC) with molecules containing Azide groups.

HY-169322

APL-1081 Mal-Exo-EVC-MMAE	Drug-Linker Conjugates for ADC Microtubule/Tubulin	Cancer
APL-1081 (Mal-Exo-EVC-MMAE) is part of an antibody-conjugated active molecule (ADC). APL-1081 is conjugated with an ADC linker (peptide Mal-Exo-EEVC) and a potent tubulin polymerization inhibitor, MMAE (HY-15162) .

HY-164995

L1BC8	PROTACs Epigenetic Reader Domain Drug-Linker Conjugates for ADC	Cancer
L1BC8 (compound 13a) is a BRD4 PROTAC degrader with anticancer effects. L1BC8 is also a *drug-linker conjugate* for ADC** that can be used for the synthesis of ADCs. The resulting BRD4-degrader antibody conjugates exhibit potent and antigen-dependent BRD4 degradation and antiproliferation activities in cell-based experiments. (Pink: BRD4 ligand (HY-129939); Blue: VHL ligand (HY-125845); Black: linker (HY-171663)) .

HY-156693A

MTvkPABC-P5 TFA	Toll-like Receptor (TLR)	Inflammation/Immunology
MTvkPABC-P5d TFA, a TLR7 agonist, is an immune stimulant. MTvkPABC-P5d TFA can be used for synthesis of immune-stimulating antibody conjugates (ISACs) .

HY-176774

L07-2	Toll-like Receptor (TLR) NF-κB	Cancer
L07-2 is a TLR7/8 agonist. L07-2 is a linker-toxin building block that can be used to synthesize immunostimulatory antibody conjugates (ISACs) for cancer research. L07-2 can be used to studies related to tumors such as non-small cell lung cancer .

HY-148346

STING agonist-20-Ala-amide-PEG2-C2-NH2	Drug-Linker Conjugates for ADC STING	Cancer
STING agonist-20-Ala-amide-PEG2-C2-NH2 is an active scaffold comprising a stimulator of interferon genes (STING). STING agonist-20-Ala-amide-PEG2-C2-NH2 can be used to synthesize immune-stimulating antibody conjugate (ISAC). STING agonist-20-Ala-amide-PEG2-C2-NH2 can be used for the research of cancer .

HY-102001

Tomaymycin DM	ADC Payload	Cancer
Tomaymycin DM is a tomaymycin derivative, PBD monomer, and DNA alkylating agent. Tomaymycin DM can serve as a payload in tumor-targeting antibody-conjugated active molecules (ADCs).

HY-145620

Zuvotolimod	ADC Linker	Inflammation/Immunology Cancer
Zuvotolimod is a myeloid cell agonist compound-linker for antibody conjugate. Zuvotolimod can be used in the research of cancer and hepatitis .

HY-145767A

SN-38-CO-DMEDA TFA	Drug Intermediate	Others
SN-38-CO-DMEDA TFA is the intermediate product for synthesizing antibody-conjugated drug LND1035 .

HY-D1546

Biotin-C2-maleimide	Fluorescent Dye	Cancer
Biotin-C2-maleimide is an antibody conjugate reagent, can bind to many biomolecules without significantly changing the biological activity of the target molecule .

HY-136260

DBCO-PEG4-Ahx-DM1	Drug-Linker Conjugates for ADC	Cancer
DBCO-PEG4-Ahx-DM1 is a agent-linker conjugate composed of a potent microtubulin inhibitor DM1 and a linker DBCO-PEG4-Ahx to make antibody agent conjugate (ADC). Mertansine (DM1) is a microtubulin inhibitor and is an antibody-conjugatable maytansinoid that is developed to overcome systemic toxicity associated with maytansine and to enhance tumor-specific delivery. DBCO-PEG4-Ahx-DM1 is a click chemistry reagent, it contains a DBCO group that can undergo strain-promoted alkyne-azide cycloaddition (SPAAC) with molecules containing Azide groups.

HY-136952

p-SCN-Bn-HOPO	Biochemical Assay Reagents Radionuclide-Drug Conjugates (RDCs)	Cancer
p-SCN-Bn-HOPO is a bifunctional chelator that forms stable octadentate complexes with Zr (IV) and ⁸⁹Zr ⁴⁺ via four 1,2-hydroxypyridone groups. p-SCN-Bn-HOPO conjugates with antibodies through the formation of thiourea bonds with lysine residues, and enables efficient ⁸⁹Zr radiolabeling under mild conditions. p-SCN-Bn-HOPO inhibits bone uptake of free radiometals, stabilizes radiometal-antibody conjugates, and achieves PET imaging with low background and enhanced tumor-to-organ contrast. p-SCN-Bn-HOPO can be used in breast cancer-related research .

HY-148346A

STING agonist-20-Ala-amide-PEG2-C2-NH2 TFA	Drug-Linker Conjugates for ADC STING	Cancer
STING agonist-20-Ala-amide-PEG2-C2-NH2 (Compound 30b) TFA is an active scaffold comprising a stimulator of interferon genes (STING). STING agonist-20-Ala-amide-PEG2-C2-NH2 TFA can be used to synthesize immune-stimulating antibody conjugate (ISAC). STING agonist-20-Ala-amide-PEG2-C2-NH2 TFA can be used for the research of cancer .

HY-W426106

Gly-NH-CH2-Boc	ADC Linker	Cancer
Gly-NH-CH2-Boc is a cleavable ADC linker that can be used to synthesize antibody-conjugated active molecules (ADC) .

HY-19318G

Fmoc-Val-Cit-PAB	ADC Linker	Cancer
Fmoc-Val-Cit-PAB GMP is a GMP grade Fmoc-Val-Cit-PAB (HY-19318). Fmoc-Val-Cit-PAB is a cleavable antibody-conjugated active molecule (ADC) commonly used linker.

HY-155791

SMCC-NH-CH2-triazole-PEG8-oxydiacetamide-Lys(MTT)-PAB	ADC Linker	Cancer
SMCC-NH-CH2-triazole-PEG8-oxydiacetamide-Lys(MTT)-PAB (Page 7, Compound C) is an ADC linker that can be used for the synthesis of antibody-conjugated active molecules (ADC) .

HY-150075

STING agonist-19	STING	Others
STING agonist-19 can be used to synthesize ISAC (immune-stimulating antibody conjugates) molecule.

HY-112901

DC41	ADC Payload	Cancer
DC41 is a DC1 derivative. DC1, a simplified analogue of CC-1065, is an antibody conjugate of cytotoxic DNA alkylators for the targeted treatment of cancer .

HY-156693

MTvkPABC-P5	Toll-like Receptor (TLR)	Inflammation/Immunology
MTvkPABC-P5d, a TLR7 agonist, is an immune stimulant. MTvkPABC-P5d can be used for synthesis of immune-stimulating antibody conjugates (ISACs) .

HY-112900

DC41SMe	ADC Payload	Cancer
DC41SMe, a DC1 derivative, shows cytotoxicity in Ramos, Namalwa, and HL60/s cells with IC₅₀s ranging from 18-25 pM. DC1, a simplified analogue of CC-1065, is an antibody conjugate of cytotoxic DNA alkylators for the targeted treatment of cancer .

HY-147215

UC-1V150	Toll-like Receptor (TLR)	Inflammation/Immunology
UC-1V150 is a specific TLR7 (Toll-like receptor) agonist that stimulates cellular immune responses and has anti-tumor activity. UC-1V150 can be used to synthesize ISAC (Immune-Stimulating Antibody Conjugates) molecule .

HY-147236

TLR7/8 agonist 7	Toll-like Receptor (TLR)	Inflammation/Immunology
TLR7/8 agonist 7 (compound 10) is a TLR7/8 agonist. TLR7/8 agonist 7 activates a variety of immune cells and it can be used to synthesize *immune stimulating antibody conjugate* (ISAC)** molecules. TLR7/8 agonist 7 can be used for the research of immunity .

HY-153196

Tetra-O-acetyl-β-D-galactopyranosyl-Ph-CH2-(4-nitrophenyl)carbonate-Fmoc	ADC Linker	Others
Tetra-O-acetyl-β-D-galactopyranosyl-Ph-CH2-(4-nitrophenyl)carbonate-Fmoc (Example 2.28.6) is an ADC linker that can be used to synthesize antibody-conjugated active molecules (ADCs) .

HY-159665

CDLI-5	E3 Ligase Ligand-Linker Conjugates	Cancer
CDLI-5 is a cereblon degrader-linker conjugate, and can be used for synthesis of cereblon degrader antibody conjugates (cDACs) .

HY-165164

Methotrexate-alpha-alanine	Drug Intermediate	Cancer
Methotrexate-alpha-alanine is a prodrug for activation by enzyme-monoclonal antibody conjugates of Methotrexate (HY-14519). Methotrexate-alpha-alanine shows cytotoxicity .

HY-126668A

Mal-PEG4-VC-PAB-DMEA TFA	ADC Linker	Cancer
Mal-PEG4-VC-PAB-DMEA TFA is a degradable ADC linker containing a maleimide group and can be used to synthesize antibody conjugate active molecules (ADCs) .

HY-129937

(S)-GNE-987	PROTACs Epigenetic Reader Domain	Cancer
(S)-GNE-987 (compound 4), the GNE-987 (a chimeric BET degrader) hydroxy-proline epimer, abrogates binding to von Hippel-Lindau and does not degrade BRD4 protein. (S)-GNE-987 binds to the BRD4 BD1(IC₅₀=4 nM) and BD2 (3.9 nM) bromodomains and can be used to design PROTAC-Antibody Conjugate (PAC) .

HY-155665

Gly-amide-OMe-Cbz	ADC Linker	Cancer
NH2-CH-CONH-CH2-O-CH2-Cbz (Page 3, Compound E) is an ADC linker that can be used for the synthesis of antibody-conjugated active molecules (ADC) .

HY-180467

Neu5Ac-2Galβ1-3Glc-oxazoline-(2)Me	ADC Linker	Cancer
Neu5Ac-2Galβ1-3Glc-oxazoline-(2)Me (Compound G12) is a disaccharide linker. Neu5Ac-2Galβ1-3Glc-oxazoline-(2)Me can be efficiently recognized by the endo-glycosidase Endo-S2 and can be directedly transferred to the conserved N-glycosylation site (Asn297 position) of the antibody's Fc domain through enzymatic catalytic reactions, thereby achieving site-specific modification of the antibody. Neu5Ac-2Galβ1-3Glc-oxazoline-(2)Me can be used for for the synthesis of antibody-conjugated drugs (ADCs) .

HY-183939

L1-CIDE-BRM1-13	PROTAC-Linker Conjugates for PAC	Others
L1-CIDE-BRM1-13 (Compound 15) is a linker-drug precursor moiety formed by the covalent conjugation of a PROTAC degrader with a linker for degrader-antibody conjugates (DACs). L1-CIDE-BRM1-13 can be used for the synthesis of DACs .

HY-19792S2

Mertansine-d3 DM1-d₃; Maytansinoid DM1-d₃	Isotope-Labeled Compounds Microtubule/Tubulin ADC Payload	Cancer
Mertansine-d₃ (DM1-d₃) is the deuterium labeled Mertansine (HY-19792). Mertansine (DM1) is a microtubulin inhibitor and is an antibody-conjugatable maytansinoid that is developed to overcome systemic toxicity associated with maytansine and to enhance tumor-specific delivery. Mertansine can be attached to a monoclonal antibody with a linker to create an antibody-drug conjugate (ADC) .

HY-19792S

Mertansine-13C,d3 DM1-¹³C,d₃; Maytansinoid DM1-¹³C,d₃	Isotope-Labeled Compounds Microtubule/Tubulin ADC Payload	Cancer
Mertansine- ¹³C,d₃ (DM1- ¹³C,d₃) is the ¹³C- and deuterium labeled Mertansine (HY-19792). Mertansine (DM1) is a microtubulin inhibitor and is an antibody-conjugatable maytansinoid that is developed to overcome systemic toxicity associated with maytansine and to enhance tumor-specific delivery. Mertansine can be attached to a monoclonal antibody with a linker to create an antibody-drug conjugate (ADC) .

Cat. No.	Product Name	Type

HY-P99016B

Enfortumab vedotin-ejfv (solution)

1 Publications Verification

Fluorescent Dyes

Enfortumab vedotin-ejfv (solution) is an anti-Nectin-4 antibody-drug conjugate (ADC). Enfortumab vedotin-ejfv (solution) is a fully humanized IgG1 antibody conjugated to the microtubule disrupting agent MMAE (HY-15162) via a protease-cleavable Val-Cit linker. The antibody portion is Enfortumab (HY-P99016), and the drug-linker conjugate for ADC is VcMMAE (HY-15575). Nectin-4 is an adhesion protein involved in cellular processes and tumorigenesis, and Enfortumab vedotin-ejfv (solution) is indicated for the inhibition of locally advanced or metastatic urothelial carcinoma .

HY-P99016A

Enfortumab vedotin-ejfv

1 Publications Verification

Fluorescent Dyes

Enfortumab vedotin-ejfv is an anti-Nectin-4 antibody-drug conjugate. Enfortumab vedotin-ejfv is a fully humanized IgG1 antibody conjugated to the microtubule disrupting agent MMAE (HY-15162) via a protease-cleavable Val-Cit linker. The antibody portion is Enfortumab (HY-P99016), and the drug-linker conjugate for ADC is VcMMAE (HY-15575). Nectin-4 is an adhesion protein involved in cellular processes and tumorigenesis, and Enfortumab vedotin-ejfv is indicated for the inhibition of locally advanced or metastatic urothelial carcinoma .

HY-164535

Maridebart cafraglutide

AMG 133

Fluorescent Dyes

Maridebart cafraglutide (AMG 133) is a long-acting peptide-antibody conjugate that combines GLP-1 receptor agonist with glucose-dependent insulinotropic polypeptide (GIP) receptor antagonism. Maridebart cafraglutide shows antagonist activity against human, cynomolgus monkey and rat GIPR with IC₅₀ values of 46.4 nM, 26.5 nM, 822.3 nM, respectively. Maridebart cafraglutide shows agonist activity against human, cynomolgus monkey, rat and mouse GLP-1R with EC₅₀ values of 24.4 pM, 5.7 pM, 2.4 pM and 123 pM, respectively. Maridebart cafraglutide can be used for the study of obesity and type 2 diabetes .

HY-171821

PF-08046054 SGN-PDL1V	Fluorescent Dyes
PF-08046054 (SGN-PDL1V) is a PD-L1-directed Antibody-drug conjugate (ADC), which is comprised of an anti-PD-L1 antibody conjugated to VcMMAE (HY-15575). PF-08046054 is direct cytotoxicity to PD-L1-expressing tumor cells via the intracellular delivery of MMAE. PF-08046054 can be used for the study of solid tumors

HY-D1546

Biotin-C2-maleimide	Fluorescent Dyes
Biotin-C2-maleimide is an antibody conjugate reagent, can bind to many biomolecules without significantly changing the biological activity of the target molecule .

HY-19318G

Fmoc-Val-Cit-PAB	Fluorescent Dyes
Fmoc-Val-Cit-PAB GMP is a GMP grade Fmoc-Val-Cit-PAB (HY-19318). Fmoc-Val-Cit-PAB is a cleavable antibody-conjugated active molecule (ADC) commonly used linker.

HY-D3334

PE-CF594

Fluorescent Dyes

PE-CF594 is a labeled monoclonal antibody conjugate that specifically binds to HLA-DR on the surface of monocytes and B cells, while acting as a signal attenuator. Through steric hindrance and a possible fluorescence resonance energy transfer mechanism, PE-CF594 specifically reduces the fluorescence intensity of PE-CD124 staining, but does not interfere with the staining of other PE-labeled antibodies such as CD40, CD4 or CD14. PE-CF594 can also be used to detect the emission signal of mt-Keima after excitation with a 561-nm laser, thereby effectively evaluating mitophagy activity .

Cat. No.	Product Name	Target	Research Area	Image

HY-P99016B

Enfortumab vedotin-ejfv (solution) 1 Publications Verification	Antibody-Drug Conjugates (ADCs) Nectin-4	Cancer
Enfortumab vedotin-ejfv (solution) is an anti-Nectin-4 antibody-drug conjugate (ADC). Enfortumab vedotin-ejfv (solution) is a fully humanized IgG1 antibody conjugated to the microtubule disrupting agent MMAE (HY-15162) via a protease-cleavable Val-Cit linker. The antibody portion is Enfortumab (HY-P99016), and the drug-linker conjugate for ADC is VcMMAE (HY-15575). Nectin-4 is an adhesion protein involved in cellular processes and tumorigenesis, and Enfortumab vedotin-ejfv (solution) is indicated for the inhibition of locally advanced or metastatic urothelial carcinoma .

HY-141606

Anetumab ravtansine BAY 94-9343	Microtubule/Tubulin Antibody-Drug Conjugates (ADCs)	Cancer
Anetumab ravtansine (BAY 94-9343) is a selective and highly potent **antibody-drug conjugate (ADC) to target maytansinoid tubulin*. Anetumab ravtansine consists of a human anti-mesothelin antibody conjugated* to the maytansinoid tubulin inhibitor DM4. Anetumab ravtansine shows antitumor efficacy correlated with the amount of mesothelin expressed in patient-derived xenograft tumor models .

HY-P991501

Meplazumab HcHAb18	ADC Antibody Transmembrane Glycoprotein SARS-CoV	Infection Cancer
Meplazumab (HcHAb18) is a humanized anti-CD147 IgG1 antibody a K_d of 0.47 nM. Meplazumab shows anti-SARS-CoV-2 and antitumor activity. Meplazumab conjugated with DM1 can form an antibody-conjugated drug ( HcHAb18-DM1), which induces G2/M phase cell cycle arrest and exerts antiproliferative activity in cancer cells. Meplazumab can be used for the researches of COVID-19 pneumonia and non-small cell lung cancer .

HY-P990627

Anti-EphA2 Antibody (1C1) MEDI-547 antibody	ADC Antibody Ephrin Receptor	Cancer
Anti-EphA2 Antibody (1C1) (MEDI-547 antibody) is an anti-EphA2 monoclonal antibody. Anti-EphA2 Antibody (1C1) can induce degradation of EphA2 protein. Anti-EphA2 Antibody (1C1) conjugated with McMMAF (HY-15578) can form an antibody-conjugated drugs, which has potent antitumor activity. Anti-EphA2 Antibody (1C1) can be used for the research of cancer, such as prostate cancer and glioma .

HY-P9S0124

Anti-CD33 Antibody (OR000283) ORM-6151 Antibody; BMS-986497 Antibody		Cancer
Anti-CD33 Antibody (OR000283) (ORM-6151 Antibody; BMS-986497 Antibody) is an antibody targeting CD33. It is generated by grafting the FAb (H&L) sequence of Gemtuzumab (HY-P99971) onto an IgG1 Fc carrying the N297A mutation, which inhibits Fc-γR binding. Anti-CD33 Antibody (OR000283) can be used to construct degrader-antibody conjugates (DACs), such as ORM-6151 (HY-171792) .

Cat. No.	Product Name	Chemical Structure

HY-19792S2

Mertansine-d3
Mertansine-d₃ (DM1-d₃) is the deuterium labeled Mertansine (HY-19792). Mertansine (DM1) is a microtubulin inhibitor and is an antibody-conjugatable maytansinoid that is developed to overcome systemic toxicity associated with maytansine and to enhance tumor-specific delivery. Mertansine can be attached to a monoclonal antibody with a linker to create an antibody-drug conjugate (ADC) .

HY-19792S

Mertansine-13C,d3

Mertansine- ¹³C,d₃ (DM1- ¹³C,d₃) is the ¹³C- and deuterium labeled Mertansine (HY-19792). Mertansine (DM1) is a microtubulin inhibitor and is an antibody-conjugatable maytansinoid that is developed to overcome systemic toxicity associated with maytansine and to enhance tumor-specific delivery. Mertansine can be attached to a monoclonal antibody with a linker to create an antibody-drug conjugate (ADC) .

Cat. No.	Product Name		Classification

HY-136261

DM1-PEG4-DBCO		DBCO ADC Synthesis
DM1-(PEG)4-DBCO is a agent-linker conjugate composed of a potent microtubulin inhibitor DM1 and a linker DBCO-PEG4-Ahx to make antibody agent conjugate (ADC). Mertansine (DM1) is a microtubulin inhibitor and is an antibody-conjugatable maytansinoid that is developed to overcome systemic toxicity associated with maytansine and to enhance tumor-specific delivery. DM1-PEG4-DBCO is a click chemistry reagent, it contains a DBCO group that can undergo strain-promoted alkyne-azide cycloaddition (SPAAC) with molecules containing Azide groups.

HY-136260

DBCO-PEG4-Ahx-DM1		DBCO ADC Synthesis
DBCO-PEG4-Ahx-DM1 is a agent-linker conjugate composed of a potent microtubulin inhibitor DM1 and a linker DBCO-PEG4-Ahx to make antibody agent conjugate (ADC). Mertansine (DM1) is a microtubulin inhibitor and is an antibody-conjugatable maytansinoid that is developed to overcome systemic toxicity associated with maytansine and to enhance tumor-specific delivery. DBCO-PEG4-Ahx-DM1 is a click chemistry reagent, it contains a DBCO group that can undergo strain-promoted alkyne-azide cycloaddition (SPAAC) with molecules containing Azide groups.

Cat. No.	Product Name	Target	Research Areas	Chemical Structure

HY-19318G

Fmoc-Val-Cit-PAB	ADC Linker	Cancer
Fmoc-Val-Cit-PAB GMP is a GMP grade Fmoc-Val-Cit-PAB (HY-19318). Fmoc-Val-Cit-PAB is a cleavable antibody-conjugated active molecule (ADC) commonly used linker.

Inquiry Online

Your information is safe with us. * Required Fields.

MCE Japan Authorized Agent ナミキ商事株式会社コスモ・バイオ株式会社重松貿易株式会社
Salutation			Country or Region *
Applicant Name *			Organization Name *
Department *
Email Address *			Product Name *
Cat. No.			Requested quantity *
Phone Number *
Remarks

Inquiry Online

Inquiry Information

Product Name:
Cat. No.:
Quantity:
MCE Japan Authorized Agent: